4D Molecular Therapeutics, Inc. (FDMT): Total Liabilities
$61.05M
As of 2025-12-31
$84.96M
As of 2026-06-30
+26.0%
3-year compound annual growth
+13.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.05M | +22.6% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $49.78M | +55.3% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $32.06M | +5.1% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $30.51M | -11.3% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $34.38M | +7.6% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $31.94M | +13.2% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $28.22M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $61.05M | +22.6% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $410.94M | +15.6% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $343.26M | -17.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $30.80M | -21.7% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $237.55M | -4.4% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
Compare FDMT, MGTX, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗